Physician profile
Thomas E Dannals
NPI 1316987100
$5,211.98
in general payments reported to CMS, 2019-2025
20 companies · $432 in 2025
The $432 reported for 2025 was more than what 88% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $261 · 2021: $929 · 2022: $977 · 2023: $709 · 2024: $874 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,015.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,220.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $806.06 | 2019-2024 | |
| Abbvie INC. | $715.77 | 2021-2025 | Dalvance |
| Janssen Pharmaceuticals, INC | $544.92 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $372.98 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $271.54 | 2019-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.53 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Gilead Sciences, INC. | $235.46 | 2021-2024 | Veklury |
| Astrazeneca Pharmaceuticals LP | $192.23 | 2019-2023 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $172.08 | 2019 | |
| Sunovion Pharmaceuticals INC. | $110.88 | 2019 | |
| Alexion Pharmaceuticals, INC. | $93.22 | 2019-2024 | Ultomiris |
| Novo Nordisk INC | $66.98 | 2023-2024 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.32 | 2020-2025 | Xifaxan |
| Electromed, INC. | $27.99 | 2023 | Smartvest |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $27.77 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $24.98 | 2023 | Nuzyra |
| Cmp Pharma, INC. | $22.15 | 2021 | |
| Smith+Nephew, INC. | $19.44 | 2025 | Collagenase Santyl |
| Philips North America LLC | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dannals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.